Integrative Bladder Cancer Treatment Platform

A comprehensive system integrating antigen presenting cells, IL-15 based superagonists, and cutting-edge technologies like blockchain, AI, IoT, and nanomaterials to revolutionize bladder cancer treatment and patient care.

The original patent disclosed a vaccine composition for treating bladder cancer using antigen presenting cells and IL-15 based superagonists. However, this invention had limitations in tracking patient treatment and response, predicting treatment outcomes, and ensuring secure data storage and sharing. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful and efficient system.

The integrative platform comprises a composition including antigen presenting cells isolated from a subject treated with Bacillus Calmette-Guerin (BCG) and cultured with IL-15 based superagonists. This composition is administered to bladder cancer patients and tracked using a blockchain-based platform, which ensures secure data storage and sharing. Artificial intelligence is used to analyze patient data and predict treatment outcomes, while an IoT network enables remote monitoring and control of devices delivering the composition. Additionally, a machine learning model is trained on patient data to predict treatment outcomes, and a nanomaterial-based delivery system targets the composition to bladder cancer cells.

The new inventive concept's novelty lies in the synergistic integration of antigen presenting cells, IL-15 based superagonists, and distinct technologies like blockchain, AI, IoT, and nanomaterials. This integration provides a non-obvious solution to the limitations of the original patent, enabling a more efficient, secure, and effective treatment of bladder cancer.

Alternative embodiments may include using different types of immunotherapeutic primed antigen presenting cells, varying the IL-15 based superagonist complex, or incorporating other emerging technologies like quantum computing or bioprinting. Variations may also involve adapting the platform for treating other types of cancer or diseases.

The integrative bladder cancer treatment platform has significant commercial potential in the oncology and healthcare industries, with a target market including hospitals, research institutions, and pharmaceutical companies. The platform's ability to enhance treatment outcomes, reduce costs, and ensure secure data storage and sharing makes it an attractive solution for stakeholders in the healthcare ecosystem.